Jesús
San Miguel Izquierdo
Consultor Investigador
Champalimaud Foundation
Lisboa, PortugalPublicaciones en colaboración con investigadores/as de Champalimaud Foundation (3)
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
BMC Cancer, Vol. 21, Núm. 1
2020
-
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
The Lancet, Vol. 395, Núm. 10218, pp. 132-141